PMC:7381711 / 5557-6452 JSON TXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-UBERON

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T4","span":{"begin":220,"end":226},"obj":"Body_part"},{"id":"T5","span":{"begin":607,"end":613},"obj":"Body_part"}],"attributes":[{"id":"A4","pred":"uberon_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/UBERON_0000055"},{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0000055"}],"text":"In addition to laboratory and histopathological evidence of disordered coagulation and endothelial injury, several reports suggest that patients with COVID-19 are at high risk for developing clinically significant large-vessel thrombosis. Early anecdotal evidence of venous thromboembolism (VTE) in critically ill patients has been confirmed by multiple case series describing high rates of VTE in COVID-19, with incidence estimates ranging between 8% and 54% (18, 22), significantly exceeding those reported in critically ill patients with H1N1 influenza of 2% (36) and sepsis of 5% (30). Reports of large-vessel strokes in patients, including those younger than 50 yr, infected with SARS-CoV-2 also suggest hypercoagulability (28). Concordantly, a postmortem study of 12 patients positive for COVID-19 found thrombosis in 58% of cases, which was found to be responsible for 25% of deaths (45)."}

LitCovid-PubTator

LitCovid-PD-MONDO

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T46","span":{"begin":99,"end":105},"obj":"Disease"},{"id":"T47","span":{"begin":150,"end":158},"obj":"Disease"},{"id":"T48","span":{"begin":227,"end":237},"obj":"Disease"},{"id":"T49","span":{"begin":267,"end":289},"obj":"Disease"},{"id":"T50","span":{"begin":291,"end":294},"obj":"Disease"},{"id":"T51","span":{"begin":391,"end":394},"obj":"Disease"},{"id":"T52","span":{"begin":398,"end":406},"obj":"Disease"},{"id":"T53","span":{"begin":541,"end":555},"obj":"Disease"},{"id":"T54","span":{"begin":546,"end":555},"obj":"Disease"},{"id":"T55","span":{"begin":614,"end":621},"obj":"Disease"},{"id":"T57","span":{"begin":685,"end":693},"obj":"Disease"},{"id":"T58","span":{"begin":685,"end":689},"obj":"Disease"},{"id":"T59","span":{"begin":709,"end":727},"obj":"Disease"},{"id":"T60","span":{"begin":795,"end":803},"obj":"Disease"},{"id":"T61","span":{"begin":810,"end":820},"obj":"Disease"}],"attributes":[{"id":"A46","pred":"mondo_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/MONDO_0021178"},{"id":"A47","pred":"mondo_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A48","pred":"mondo_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"},{"id":"A49","pred":"mondo_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/MONDO_0005399"},{"id":"A50","pred":"mondo_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/MONDO_0005399"},{"id":"A51","pred":"mondo_id","subj":"T51","obj":"http://purl.obolibrary.org/obo/MONDO_0005399"},{"id":"A52","pred":"mondo_id","subj":"T52","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A53","pred":"mondo_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/MONDO_0005460"},{"id":"A54","pred":"mondo_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A55","pred":"mondo_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/MONDO_0005098"},{"id":"A56","pred":"mondo_id","subj":"T55","obj":"http://purl.obolibrary.org/obo/MONDO_0011057"},{"id":"A57","pred":"mondo_id","subj":"T57","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A58","pred":"mondo_id","subj":"T58","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A59","pred":"mondo_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/MONDO_0002305"},{"id":"A60","pred":"mondo_id","subj":"T60","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A61","pred":"mondo_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/MONDO_0000831"}],"text":"In addition to laboratory and histopathological evidence of disordered coagulation and endothelial injury, several reports suggest that patients with COVID-19 are at high risk for developing clinically significant large-vessel thrombosis. Early anecdotal evidence of venous thromboembolism (VTE) in critically ill patients has been confirmed by multiple case series describing high rates of VTE in COVID-19, with incidence estimates ranging between 8% and 54% (18, 22), significantly exceeding those reported in critically ill patients with H1N1 influenza of 2% (36) and sepsis of 5% (30). Reports of large-vessel strokes in patients, including those younger than 50 yr, infected with SARS-CoV-2 also suggest hypercoagulability (28). Concordantly, a postmortem study of 12 patients positive for COVID-19 found thrombosis in 58% of cases, which was found to be responsible for 25% of deaths (45)."}

LitCovid-PD-CLO

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T21","span":{"begin":220,"end":226},"obj":"http://purl.obolibrary.org/obo/UBERON_0000055"},{"id":"T22","span":{"begin":323,"end":326},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T23","span":{"begin":461,"end":463},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"},{"id":"T24","span":{"begin":465,"end":467},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T25","span":{"begin":563,"end":565},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T26","span":{"begin":607,"end":613},"obj":"http://purl.obolibrary.org/obo/UBERON_0000055"},{"id":"T27","span":{"begin":748,"end":749},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T28","span":{"begin":891,"end":893},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"}],"text":"In addition to laboratory and histopathological evidence of disordered coagulation and endothelial injury, several reports suggest that patients with COVID-19 are at high risk for developing clinically significant large-vessel thrombosis. Early anecdotal evidence of venous thromboembolism (VTE) in critically ill patients has been confirmed by multiple case series describing high rates of VTE in COVID-19, with incidence estimates ranging between 8% and 54% (18, 22), significantly exceeding those reported in critically ill patients with H1N1 influenza of 2% (36) and sepsis of 5% (30). Reports of large-vessel strokes in patients, including those younger than 50 yr, infected with SARS-CoV-2 also suggest hypercoagulability (28). Concordantly, a postmortem study of 12 patients positive for COVID-19 found thrombosis in 58% of cases, which was found to be responsible for 25% of deaths (45)."}

LitCovid-PD-GO-BP

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T5","span":{"begin":71,"end":82},"obj":"http://purl.obolibrary.org/obo/GO_0050817"}],"text":"In addition to laboratory and histopathological evidence of disordered coagulation and endothelial injury, several reports suggest that patients with COVID-19 are at high risk for developing clinically significant large-vessel thrombosis. Early anecdotal evidence of venous thromboembolism (VTE) in critically ill patients has been confirmed by multiple case series describing high rates of VTE in COVID-19, with incidence estimates ranging between 8% and 54% (18, 22), significantly exceeding those reported in critically ill patients with H1N1 influenza of 2% (36) and sepsis of 5% (30). Reports of large-vessel strokes in patients, including those younger than 50 yr, infected with SARS-CoV-2 also suggest hypercoagulability (28). Concordantly, a postmortem study of 12 patients positive for COVID-19 found thrombosis in 58% of cases, which was found to be responsible for 25% of deaths (45)."}

LitCovid-sentences

{"project":"LitCovid-sentences","denotations":[{"id":"T39","span":{"begin":0,"end":238},"obj":"Sentence"},{"id":"T40","span":{"begin":239,"end":589},"obj":"Sentence"},{"id":"T41","span":{"begin":590,"end":733},"obj":"Sentence"},{"id":"T42","span":{"begin":734,"end":895},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In addition to laboratory and histopathological evidence of disordered coagulation and endothelial injury, several reports suggest that patients with COVID-19 are at high risk for developing clinically significant large-vessel thrombosis. Early anecdotal evidence of venous thromboembolism (VTE) in critically ill patients has been confirmed by multiple case series describing high rates of VTE in COVID-19, with incidence estimates ranging between 8% and 54% (18, 22), significantly exceeding those reported in critically ill patients with H1N1 influenza of 2% (36) and sepsis of 5% (30). Reports of large-vessel strokes in patients, including those younger than 50 yr, infected with SARS-CoV-2 also suggest hypercoagulability (28). Concordantly, a postmortem study of 12 patients positive for COVID-19 found thrombosis in 58% of cases, which was found to be responsible for 25% of deaths (45)."}

LitCovid-PD-HP

{"project":"LitCovid-PD-HP","denotations":[{"id":"T11","span":{"begin":274,"end":289},"obj":"Phenotype"},{"id":"T12","span":{"begin":571,"end":577},"obj":"Phenotype"},{"id":"T13","span":{"begin":709,"end":727},"obj":"Phenotype"}],"attributes":[{"id":"A11","pred":"hp_id","subj":"T11","obj":"http://purl.obolibrary.org/obo/HP_0001907"},{"id":"A12","pred":"hp_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/HP_0100806"},{"id":"A13","pred":"hp_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/HP_0100724"}],"text":"In addition to laboratory and histopathological evidence of disordered coagulation and endothelial injury, several reports suggest that patients with COVID-19 are at high risk for developing clinically significant large-vessel thrombosis. Early anecdotal evidence of venous thromboembolism (VTE) in critically ill patients has been confirmed by multiple case series describing high rates of VTE in COVID-19, with incidence estimates ranging between 8% and 54% (18, 22), significantly exceeding those reported in critically ill patients with H1N1 influenza of 2% (36) and sepsis of 5% (30). Reports of large-vessel strokes in patients, including those younger than 50 yr, infected with SARS-CoV-2 also suggest hypercoagulability (28). Concordantly, a postmortem study of 12 patients positive for COVID-19 found thrombosis in 58% of cases, which was found to be responsible for 25% of deaths (45)."}

2_test

{"project":"2_test","denotations":[{"id":"32519894-32291094-2138157","span":{"begin":461,"end":463},"obj":"32291094"},{"id":"32519894-32353746-2138158","span":{"begin":465,"end":467},"obj":"32353746"},{"id":"32519894-19132200-2138159","span":{"begin":563,"end":565},"obj":"19132200"},{"id":"32519894-16310605-2138160","span":{"begin":585,"end":587},"obj":"16310605"},{"id":"32519894-32343504-2138161","span":{"begin":729,"end":731},"obj":"32343504"},{"id":"32519894-32374815-2138162","span":{"begin":891,"end":893},"obj":"32374815"}],"text":"In addition to laboratory and histopathological evidence of disordered coagulation and endothelial injury, several reports suggest that patients with COVID-19 are at high risk for developing clinically significant large-vessel thrombosis. Early anecdotal evidence of venous thromboembolism (VTE) in critically ill patients has been confirmed by multiple case series describing high rates of VTE in COVID-19, with incidence estimates ranging between 8% and 54% (18, 22), significantly exceeding those reported in critically ill patients with H1N1 influenza of 2% (36) and sepsis of 5% (30). Reports of large-vessel strokes in patients, including those younger than 50 yr, infected with SARS-CoV-2 also suggest hypercoagulability (28). Concordantly, a postmortem study of 12 patients positive for COVID-19 found thrombosis in 58% of cases, which was found to be responsible for 25% of deaths (45)."}

PMC:7381711 / 5557-6452 JSONTXT

Annnotations TAB JSON ListView MergeView

PMC:7381711 / 5557-6452 JSON TXT